Pharmacy Fungus Plunges Doctors Into 'Gray Zone'
Physicians trying to treat the hundreds of patients infected by black mold that that contaminated steroids distributed by a Massachusetts compounding pharmacy last month are finding a lack of evidence for what they should do first.
"We're basically in a gray zone," says Shmuel Shoham, MD, an internist and infectious disease specialist at Johns Hopkins University. "What makes this process difficult is that we're just now learning about the natural history of this infection."
Almost nothing is known about Exserohilum rostratum, the black mold or fungus implicated in the current outbreak in which an estimated 14,000 people have been exposed, with 438 patients infected so far in 19 states.
"Up until two months ago, when the first case was diagnosed, nobody had ever seen, in this location of the body, this particular type of infection in these types of patients," Shoham says. "And so what we've had to do is extrapolate data from other similar infections, organisms causing infections at another site, see how it behaves in the laboratory... and try to sort through to make a reasonable treatment plan."
Shoham and colleague, Kieren Marr, MD, director of transplant and oncology infections diseases at Johns Hopkins, published an article in the current online edition of the Annals of Internal Medicine.Itdetails what they've seen in several dozen infected patients treated at their hospital.
- New G-Codes to Pay Doctors for Broad Array of Non-Face-to-Face Care
- CMS Sets 2014 Pay Rates for Hospital Outpatient and Physician Services
- Telehealth Improves Patient Care in ICUs
- Hospital M&A Volume Up, Value Down in 3Q
- 50 Years of Fighting Pressure Ulcers Called Into Question
- Douglas Hawthorne—A Chance to Do Something Big
- States Rejecting Medicaid Expansion Forgo Billions in Federal Funds
- Why You Should Involve Patients in Nursing Handoffs
- Nonprofit Hospital Outlook 'Negative' in 2014
- The 5 Biggest Healthcare Finance Trouble Spots